Intranasal administration of 99mTc-topiramate-loaded phospholipid magnesome potential route for enhanced brain delivery: Characterization, biodistribution, and pharmacokinetic behaviors

Abstract

Topiramate (Tp) is an antiepileptic medication that works in a variety of ways. It has been shown to be effective in treating several epileptic diseases in adults and children, as well as Lennox–Gastaut syndrome and migraine prophylaxis. The goal of this study was to create a Tp-loaded phospholipid magnesome (PM) that might be used to improve brain targeting for early detection and/or therapy of brain disorders. Tp was radiolabeled with 99mTc with a percent radiochemical yield (RCY) of 91.10% ± 0.26%. Various approaches were used to check the quality of 99mTc-Tp. In vitro, various magnesomal systems were produced and characterized. Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) were used to characterize the morphology (SEM). Higher drug targeting efficiency percent (DTE %) = 200.2% and nose-to-brain direct transport percentage (DTP %) = 98.2% were found in pharmacokinetic investigations of the optimized formula.When compared to intravenous and intranasal delivery of the same drug solution, intranasal 99mTc-Tp-loaded magnesomes can be a powerful diagnostic and/or treatment tool for a variety of brain disorders and malignancies.